[Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].

Abstract

BCR-ABL tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML). Currently, five BCR-ABL TKIs are approved for use in patients with CML, but the long-term use of these TKIs is associated with various cardiovascular events. Typical cardiovascular adverse events include pulmonary hypertension caused by dasatinib and arterial occlusive diseases caused by nilotinib and ponatinib. Although mechanisms of cardiovascular adverse events of BCR-ABL TKIs in the treatment of CML have not been clarified, differences in their inhibitory activities on off-target kinases, including those involved in vascular function, may be related to individual safety profiles. Arterial occlusive diseases are common in patients with a history of cardiovascular disease and risk of atherosclerosis. Arterial occlusive diseases, such as ischemic heart disease, ischemic cerebral disease, and peripheral arterial occlusive disease, worsen the prognosis and quality of life of patients with CML. Therefore, appropriate management strategies are required. This paper outlines cardiovascular adverse events associated with TKI treatment, including arterial obstructive diseases, pulmonary arterial hypertension, and QT interval prolongation.

• Authors: Sakiko Miyazaki
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 62 Issue 8 Pg. 1024-1028 ( 2021) ISSN: 0485-1439 [Print] Japan
• PMID: 34497188 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Fusion Proteins, bcr-abl
• Dasatinib

Topics

• Antineoplastic Agents (therapeutic use)
• Dasatinib (therapeutic use)
• Fusion Proteins, bcr-abl
• Humans
• Hypertension, Pulmonary (chemically induced)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Protein Kinase Inhibitors (adverse effects)
• Quality of Life